Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Oncology Institute (TOI) Long-Term Debt Repayments (2021 - 2025)

Oncology Institute posted quarterly Long-Term Debt Repayments of $20.0 million for Q1 2025, up 290.24% on a QoQ basis from $5.1 million in Q4 2021.

Oncology Institute (TOI) has 2 years of Long-Term Debt Repayments data on file, last reported at $20.0 million in Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Dec 2025 stood at $20.0 million (changed N/A YoY), and the FY2025 full-year result was $20.0 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2025 stood at $20.0 million, up from $5.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $20.0 million in Q1 2025 and bottomed at $94000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn 58.00 Mn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn 33.00 Mn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn 917.09 Mn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn 330.00 Mn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn 1.04 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn 44.73 Mn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn -
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn 44.28 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn -
10 Oncology Institute 477.45 Mn 447.17 Mn 139.16 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 20.00 Mn
Mar 31, 2025 20.00 Mn
Dec 31, 2021 5.13 Mn
Dec 31, 2021 5.13 Mn
Jun 30, 2021 2.00 Mn
Jun 30, 2021 2.00 Mn
Mar 31, 2021 94,000.00
Mar 31, 2021 94,000.00